Page last updated: 2024-12-04

aminopropionitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Aminopropionitrile: Reagent used as an intermediate in the manufacture of beta-alanine and pantothenic acid. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1647
CHEMBL ID1618272
CHEBI ID27413
MeSH IDM0000960

Synonyms (84)

Synonym
beta-aminoethyl cyanide
3-amino-propionitrile
nsc40641
.beta.-cyanoethylamine
.beta.-aminopropionitrile
wln: z2cn
.beta.-alaninenitrile
3-aminopropionitrile ,
propionitrile, 3-amino-
propanenitrile, 3-amino-
bapn
2-cyanoethylamine
nsc-40641
aminopropionitrile
3-aminopropanenitrile
brn 1698848
nsc 40641
beta-alaninenitrile
einecs 205-786-0
hsdb 2897
beta-cyanoethylamine
NCGC00015048-01
lopac-a-3134
LOPAC0_000055
C05670
3-aminopropiononitrile
beta-aminopropionitrile ,
151-18-8
NCGC00162054-01
h2nch2ch2cn
CHEBI:27413 ,
A0408
inchi=1/c3h6n2/c4-2-1-3-5/h1-2,4h2
agspxmvufbbbmo-uhfffaoysa-
NCGC00015048-03
AKOS000121388
38d5lj4kh2 ,
unii-38d5lj4kh2
ccris 8134
NCGC00015048-02
68130-65-4
68130-66-5
3-aminopropionitrile stabilized with k2co3
FT-0615060
beta-aminoproprionitrile
aminopropionitrile [hsdb]
3-aminopropionitrile [mi]
beta-aminopropionitrile [mart.]
beta-aminopropionitrile [green book]
beta-amino-propionitrile
aminoethylcyanide
beta-amino propionitrile
3-aminopropanonitrile
cyanoethylamine
DTXSID6048418
sodiumbitartrate,monohydrate
CHEMBL1618272 ,
.beta.-aminoethyl cyanide
c3h6n2
W-109080
3-amino-propionitrile, aldrichcpr
mfcd00014820
b-alaninenitrile
b-cyanoethylamine
b-aminoethyl cyanide
b-alaminenitrile
CS-D1507
n-(2-cyanoethyl)amine
BBL101609
STL555405
3-aminopropanitrile
aminopropionitrile (bapn)
Q3614347
3-aminopropionitrile; aminopropionitrile; bapn; n-(2-cyanoethyl)amine; nsc 40641
beta-aminopropionitrile liquid
STR02529
NCGC00015048-05
D77355
bdbm50232678
HY-Y1750
3-aminopropionitrile (stabilized with k2co3)
SB75359
?3-aminopropionitrile
EN300-21136

Research Excerpts

Overview

beta-Aminopropionitrile (BAPN) is a compound known to cause aortic aneurysms by inhibiting lysyl oxidase, a collagen cross-linking enzyme. It is an irreversible inhibitor of lysol oxidase activity, suggesting a potentially useful therapeutic of interest in oncology.

ExcerptReferenceRelevance
"β-Aminopropionitrile (BAPN) is a compound known to cause aortic aneurysms by inhibiting lysyl oxidase, a collagen cross-linking enzyme."( A novel swine model of abdominal aortic aneurysm.
Ailawadi, G; Cullen, JM; Fashandi, AZ; Johnston, WF; Lu, G; Montgomery, WG; Salmon, M; Shannon, AH; Sharma, A; Spinosa, MD; Su, G; Upchurch, GR, 2019
)
1.07
"β-Aminopropionitrile (BAPN) is an irreversible inhibitor of lysyl oxidase activity, suggesting a potentially useful therapeutic of interest in oncology."( Quantification of β-aminopropionitrile, an inhibitor of lysyl oxidase activity, in plasma and tumor of mice by liquid chromatography tandem mass spectrometry.
Bernard, D; Coste, S; Guitton, J; Le Calve, B; Machon, C; Payen, L; Riviere, M, 2014
)
1.28
"beta-Aminopropionitrile (BAPN) is a potent irreversible inhibitor of lysyl oxidase, the enzyme which initiates cross-linkage formation in elastin and collagen. "( Reaction of aortic lysyl oxidase with beta-aminopropionitrile.
Kagan, HM; Tang, SS; Trackman, PC, 1983
)
1.04
"beta-Aminopropionitrile (BAPN) is an inhibitor of the lysyl oxidase required for cross-link formation in collagen maturation. "( Experimental schistosomiasis mansoni: modulation of granulomas by inhibition of collagen cross-link formation. Preliminary report.
Giboda, M; Julis, I; Vítovec, J; Zenka, J, 1992
)
0.8
"beta-aminopropionitrile (BAPN), which is an inhibitor of the enzyme lysyl oxidase implicated in the synthesis of elastin, is able to induce in the young Wistar rat interruptions in the IEL which are morphologically very similar to those which form spontaneously."( [Formation of disruptions of the internal elastica lamina, spontaneous and BAPN induced, in arteries of stroke-prone spontaneously hypertensive rats].
Coutard, M; Osborne-Pellegrin, M, 1987
)
0.73
"Beta-aminopropionitrile (BAPN) is an inhibitor of pig plasma benzylamine oxidase. "( Reaction of pig plasma benzylamine oxidase with beta-aminopropionitrile.
Banchelli, G; Bertini, V; Bertocci, B; Buffoni, F; De Munno, A; Ignesti, G; Lodovici, M; Pirisino, R; Raimondi, L, 1985
)
1.03

Actions

ExcerptReferenceRelevance
"beta-Aminopropionitrile is known to inhibit cross-linking of collagen and is expected to enhance the flexibility of scar tissue, thereby reducing wound contracture and regression after RK."( Effects of topical treatment with beta-aminopropionitrile after radial keratotomy in the rabbit.
Armeniades, CD; Carroll, J; Constance, G; Jenkins, DE; Moorhead, LC, 1984
)
0.99

Treatment

beta-aminopropionitrile (BAPN) treatment, which irreversibly blocks lysyl oxidase, inhibited the formation of collagen crosslinks. Treatment also decreased the amount of N-acetylhexosamines in the chick embryo.

ExcerptReferenceRelevance
"beta-aminopropionitrile (BAPN) treatment, which irreversibly blocks lysyl oxidase, inhibited the formation of collagen crosslinks, prevented development of adhesive strength, and caused a buildup of GuHCl-extractable collagen crosslink precursors."( Treatment of cartilage with beta-aminopropionitrile accelerates subsequent collagen maturation and modulates integrative repair.
McGowan, KB; Sah, RL, 2005
)
1.06
"beta-Aminopropionitrile treatment also decreased the amount of N-acetylhexosamines in the chick embryo and decreased the percentage of the hexosamine esterified by nucleotides."( Alterations in glycosaminoglycan metabolism in beta-aminopropionitrile-treated chick embryos.
Elders, MJ; Hughes, ER; Smith, JD; Smith, WG, 1973
)
0.96

Toxicity

ExcerptReferenceRelevance
"The underlying etiology of the toxic oil syndrome may be related to any of several toxic contaminants."( Synergistic vascular toxicity and fatty acid anilides in the toxic oil syndrome.
Ansari, GA; Boor, PJ; Jerrells, TR; Kaphalia, BS; Khan, MF, 1991
)
0.28
" Commercially available DMAPN metabolites, administered by gavage, produced toxic effects less adverse than DMAPN."( Studies on the mechanism of urotoxic effects of N,N'-dimethylaminopropionitrile in rats and mice. 1. Biochemical and morphologic characterization of the injury and its relationship to metabolism.
Ahmed, AE; Farooqui, MY; Frankenberg, L; Ghanayem, BI; Mumtaz, MM; Rajaraman, S, 1991
)
0.52
"The joint toxic action of three binary mixtures was determined for the embryo malformation endpoint of the aquatic FETAX (frog embryo teratogenesis assay: Xenopus) test system."( Initial evaluation of developmental malformation as an end point in mixture toxicity hazard assessment for aquatic vertebrates.
Dawson, DA; Wilke, TS, 1991
)
0.28

Compound-Compound Interactions

ExcerptReferenceRelevance
"This study aimed to explore whether and how anti-lysyl oxidase (anti-LOX) combined with a vacuum device (VD) could promote penile lengthening and to evaluate the effect on erectile function."( Anti-lysyl oxidase combined with a vacuum device induces penile lengthening by remodeling the tunica albuginea.
Fu, FD; Li, T; Qin, F; Wang, R; Wu, CJ; Yuan, JH,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of topically administered beta APN was determined by measuring the degree of collagen cross-linking inhibition in the underlying granuloma tissue."( Effect of topically applied beta-aminopropionitrile on granuloma tissue biochemistry.
Chvapil, M; Dhar, SC; Gibeault, JD; Gowri, C; Lata, A, 1988
)
0.56
" Following our recently published work on the discovery of aminomethylenethiophenes (AMTs) as potent, orally bioavailable LOX/LOXL2 inhibitors, we report herein the discovery of a series of dual LOX/LOXL2 inhibitors, as well as a subseries of LOXL2-selective inhibitors, bearing an aminomethylenethiazole (AMTz) scaffold."( 2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
Aljarah, M; Brown, M; Challinor, M; Johnson, L; Lawrence, R; Leung, LMH; Lopes, F; Marais, R; Mcleary, R; Niculescu-Duvaz, D; Pearce, SP; Smithen, DA; Springer, C; Tang, H; Thomson, G, 2020
)
0.56

Dosage Studied

A mouse model of lathyrism using subcutaneous injection of up to 500 mg/kg was developed and characterized. beta-Aminopropionitrile (BAPN) induced monotonic degradation of all properties at all dose levels.

ExcerptRelevanceReference
"The use of lathyric toxins (BAPN) in low dosage (1 g/kg/day) for a period of 8 weeks caused in the rat simultaneous changes in the skin and aortic connective tissues."( [Chronic lathyrism. Protective effect of pyridinol carbamate on connective tissue lesions in the rat (author's transl)].
Bouissou, H; Foulquier, F; Julian, M; Pieraggi, MT; Vila, C, 1977
)
0.26
" In conclusion, AG at moderate dosage does not seem to influence the formation of lysyl oxidase dependent reducible cross-links of collagen."( The influence of aminoguanidine on borohydride reducible collagen cross-links and wound strength.
Andreassen, TT; Jørgensen, PH; Oxlund, H; Seyer-Hansen, M, 1991
)
0.28
" In order to investigate the mechanism of DMAPN toxicity, we carried out time-course (0-72 h) and dose-response (175-700 mg/kg) studies on the effects of DMAPN in rats and mice."( Studies on the mechanism of urotoxic effects of N,N'-dimethylaminopropionitrile in rats and mice. 1. Biochemical and morphologic characterization of the injury and its relationship to metabolism.
Ahmed, AE; Farooqui, MY; Frankenberg, L; Ghanayem, BI; Mumtaz, MM; Rajaraman, S, 1991
)
0.52
" Thirty-six hours before sacrifice, the controls and BAPN fed chicks were dosed with 35S."( Effects of B-aminopropionitrile on mineralization during endochondral ossification in chick tibia.
Hing, AK; Sandhu, HS, 1988
)
0.64
" The inefficiency of BAPN in these experiments might have been due to either inadequate dosage or wrong timing, or both."( Improvement of gliding function of flexor tendons by topically applied enriched collagen solution.
Porat, S; Rousso, M; Shoshan, S, 1980
)
0.26
" beta-Aminopropionitrile (BAPN) induced monotonic degradation of all properties at all dose levels, corresponding to the decreasing density with dosage level."( Comparison of dosage-dependent effects of beta-aminopropionitrile, sodium fluoride, and hydrocortisone on selected physical properties of cortical bone.
Hanson, D; Lees, S; Mook, HA; Page, E, 1994
)
1.03
" A β-APN dosage of 5 mg/0."( Effect of defective collagen synthesis on epithelial implant interface: lathyritic model in dogs. An experimental preliminary study.
Acikgoz, G; Cengiz, MI; Kirtiloğlu, T; Trisi, P; Wang, HL, 2012
)
0.38
" A mouse model of lathyrism using subcutaneous injection of up to 500 mg/kg β-aminopropionitrile (BAPN) was developed and characterized (60 animals across 4 dosage groups)."( Bone fracture toughness and strength correlate with collagen cross-link maturity in a dose-controlled lathyrism mouse model.
Gong, B; Kohn, DH; McNerny, EM; Morris, MD, 2015
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antirheumatic drugA drug used to treat rheumatoid arthritis.
collagen cross-linking inhibitorAny compound that inhibits collagen cross-linking.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aminopropionitrile
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency23.09990.004110.890331.5287AID493107
arylsulfatase AHomo sapiens (human)Potency0.75691.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.75190.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysyl oxidase homolog 2Rattus norvegicus (Norway rat)IC50 (µMol)0.12700.12700.12700.1270AID1430576
Protein-lysine 6-oxidaseHomo sapiens (human)IC50 (µMol)33.70000.01001.19705.0000AID1399349; AID1430573; AID1483218
Protein-lysine 6-oxidaseBos taurus (cattle)IC50 (µMol)1.99531.99531.99531.9953AID1526667
Lysyl oxidase homolog 2Mus musculus (house mouse)IC50 (µMol)0.12800.12800.12800.1280AID1430575
Lysyl oxidase homolog 3Homo sapiens (human)IC50 (µMol)0.24000.09300.17080.3100AID1399351; AID1604048
Lysyl oxidase homolog 4Homo sapiens (human)IC50 (µMol)100.00000.05900.11950.1800AID1399352
Lysyl oxidase homolog 2Homo sapiens (human)IC50 (µMol)0.56500.06600.56494.2600AID1399350; AID1430566; AID1430567; AID1430571; AID1430572; AID1483214; AID1483215; AID1483217; AID1483219; AID1526666; AID1604042; AID1604043; AID1604044
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
osteoblast differentiationProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of protein phosphorylationProtein-lysine 6-oxidaseHomo sapiens (human)
heart developmentProtein-lysine 6-oxidaseHomo sapiens (human)
response to xenobiotic stimulusProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of gene expressionProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of striated muscle tissue developmentProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
peptidyl-lysine oxidationProtein-lysine 6-oxidaseHomo sapiens (human)
bone mineralizationProtein-lysine 6-oxidaseHomo sapiens (human)
lung developmentProtein-lysine 6-oxidaseHomo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
ascending aorta developmentProtein-lysine 6-oxidaseHomo sapiens (human)
descending aorta developmentProtein-lysine 6-oxidaseHomo sapiens (human)
protein modification processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of apoptotic processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of megakaryocyte differentiationProtein-lysine 6-oxidaseHomo sapiens (human)
muscle cell cellular homeostasisProtein-lysine 6-oxidaseHomo sapiens (human)
elastic fiber assemblyProtein-lysine 6-oxidaseHomo sapiens (human)
blood vessel morphogenesisProtein-lysine 6-oxidaseHomo sapiens (human)
response to steroid hormoneProtein-lysine 6-oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProtein-lysine 6-oxidaseHomo sapiens (human)
muscle cell developmentProtein-lysine 6-oxidaseHomo sapiens (human)
cell chemotaxisProtein-lysine 6-oxidaseHomo sapiens (human)
connective tissue developmentProtein-lysine 6-oxidaseHomo sapiens (human)
DNA biosynthetic processProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of bone developmentProtein-lysine 6-oxidaseHomo sapiens (human)
cellular response to chemokineProtein-lysine 6-oxidaseHomo sapiens (human)
regulation of platelet-derived growth factor receptor-beta signaling pathwayProtein-lysine 6-oxidaseHomo sapiens (human)
collagen fibril organizationProtein-lysine 6-oxidaseHomo sapiens (human)
peptidyl-lysine oxidationProtein-lysine 6-oxidaseBos taurus (cattle)
blood vessel morphogenesisProtein-lysine 6-oxidaseBos taurus (cattle)
epithelial to mesenchymal transitionLysyl oxidase homolog 3Homo sapiens (human)
inflammatory responseLysyl oxidase homolog 3Homo sapiens (human)
peptidyl-lysine oxidationLysyl oxidase homolog 3Homo sapiens (human)
spinal cord developmentLysyl oxidase homolog 3Homo sapiens (human)
lung developmentLysyl oxidase homolog 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionLysyl oxidase homolog 3Homo sapiens (human)
roof of mouth developmentLysyl oxidase homolog 3Homo sapiens (human)
somite developmentLysyl oxidase homolog 3Homo sapiens (human)
fibronectin fibril organizationLysyl oxidase homolog 3Homo sapiens (human)
negative regulation of T-helper 17 cell lineage commitmentLysyl oxidase homolog 3Homo sapiens (human)
positive regulation of integrin-mediated signaling pathwayLysyl oxidase homolog 3Homo sapiens (human)
collagen fibril organizationLysyl oxidase homolog 3Homo sapiens (human)
collagen fibril organizationLysyl oxidase homolog 4Homo sapiens (human)
peptidyl-lysine oxidationLysyl oxidase homolog 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IILysyl oxidase homolog 2Homo sapiens (human)
response to hypoxiaLysyl oxidase homolog 2Homo sapiens (human)
epithelial to mesenchymal transitionLysyl oxidase homolog 2Homo sapiens (human)
endothelial cell proliferationLysyl oxidase homolog 2Homo sapiens (human)
sprouting angiogenesisLysyl oxidase homolog 2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysyl oxidase homolog 2Homo sapiens (human)
peptidyl-lysine oxidationLysyl oxidase homolog 2Homo sapiens (human)
collagen fibril organizationLysyl oxidase homolog 2Homo sapiens (human)
positive regulation of chondrocyte differentiationLysyl oxidase homolog 2Homo sapiens (human)
protein modification processLysyl oxidase homolog 2Homo sapiens (human)
endothelial cell migrationLysyl oxidase homolog 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionLysyl oxidase homolog 2Homo sapiens (human)
response to copper ionLysyl oxidase homolog 2Homo sapiens (human)
heterochromatin organizationLysyl oxidase homolog 2Homo sapiens (human)
negative regulation of stem cell population maintenanceLysyl oxidase homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
protein-lysine 6-oxidase activityProtein-lysine 6-oxidaseHomo sapiens (human)
copper ion bindingProtein-lysine 6-oxidaseHomo sapiens (human)
protein bindingProtein-lysine 6-oxidaseHomo sapiens (human)
collagen bindingProtein-lysine 6-oxidaseHomo sapiens (human)
small molecule bindingProtein-lysine 6-oxidaseHomo sapiens (human)
molecular adaptor activityProtein-lysine 6-oxidaseHomo sapiens (human)
protein-lysine 6-oxidase activityProtein-lysine 6-oxidaseBos taurus (cattle)
copper ion bindingProtein-lysine 6-oxidaseBos taurus (cattle)
collagen bindingProtein-lysine 6-oxidaseBos taurus (cattle)
fibronectin bindingLysyl oxidase homolog 3Homo sapiens (human)
protein-lysine 6-oxidase activityLysyl oxidase homolog 3Homo sapiens (human)
copper ion bindingLysyl oxidase homolog 3Homo sapiens (human)
protein bindingLysyl oxidase homolog 3Homo sapiens (human)
protein-lysine 6-oxidase activityLysyl oxidase homolog 4Homo sapiens (human)
copper ion bindingLysyl oxidase homolog 4Homo sapiens (human)
protein bindingLysyl oxidase homolog 4Homo sapiens (human)
protein-lysine 6-oxidase activityLysyl oxidase homolog 2Homo sapiens (human)
copper ion bindingLysyl oxidase homolog 2Homo sapiens (human)
calcium ion bindingLysyl oxidase homolog 2Homo sapiens (human)
protein bindingLysyl oxidase homolog 2Homo sapiens (human)
oligosaccharide bindingLysyl oxidase homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionProtein-lysine 6-oxidaseHomo sapiens (human)
extracellular spaceProtein-lysine 6-oxidaseHomo sapiens (human)
collagen trimerProtein-lysine 6-oxidaseHomo sapiens (human)
extracellular spaceProtein-lysine 6-oxidaseHomo sapiens (human)
collagen-containing extracellular matrixProtein-lysine 6-oxidaseHomo sapiens (human)
extracellular regionProtein-lysine 6-oxidaseBos taurus (cattle)
extracellular spaceProtein-lysine 6-oxidaseBos taurus (cattle)
extracellular regionLysyl oxidase homolog 3Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 3Homo sapiens (human)
nucleusLysyl oxidase homolog 3Homo sapiens (human)
cytoplasmLysyl oxidase homolog 3Homo sapiens (human)
membraneLysyl oxidase homolog 3Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 3Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 3Homo sapiens (human)
membraneLysyl oxidase homolog 4Homo sapiens (human)
extracellular exosomeLysyl oxidase homolog 4Homo sapiens (human)
receptor complexLysyl oxidase homolog 4Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 4Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 4Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 2Homo sapiens (human)
basement membraneLysyl oxidase homolog 2Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 2Homo sapiens (human)
nucleusLysyl oxidase homolog 2Homo sapiens (human)
nucleoplasmLysyl oxidase homolog 2Homo sapiens (human)
endoplasmic reticulumLysyl oxidase homolog 2Homo sapiens (human)
membraneLysyl oxidase homolog 2Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 2Homo sapiens (human)
chromatinLysyl oxidase homolog 2Homo sapiens (human)
collagen-containing extracellular matrixLysyl oxidase homolog 2Homo sapiens (human)
extracellular spaceLysyl oxidase homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID1430571Inhibition of full length recombinant human LOXL2 expressed in CHO cells spiked into human whole blood assessed as reduction in H2O2 production using DAP as substrate preincubated for 2 followed by substrate addition measured every 90 secs for 45 mins by 2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1526724Antifibrotic activity in CCl4-induced BALB/c mouse model of liver fibrosis assessed as reduction in liver fibrosis area at 2 mg/ml, po administered every 2 day for 6 weeks by alpha-SMA staining based microscopy2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
AID1604045Ratio of IC50 for human C-terminal His10-tagged LOXL2 (Met1 to Gln774 residues) expressed in mouse NS0 cells using cadaverine hydrochloride as substrate preincubated for 20 mins followed by substrate addition to IC50 for human C-terminal His10-tagged LOXL2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
AID1526667Inhibition of LOX in bovine aorta using putrescine as substrate preincubated with enzyme for 30 mins followed by substrate addition and measured every 2.5 mins for 30 mins by Amplex-Red oxidation assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
AID1399356Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1430583Ratio of IC50 for full length recombinant human LOXL2 expressed in CHO cells spiked into human whole blood to IC50 for full length recombinant human LOXL2 expressed in CHO cells2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1604047Inhibition of pig skin-derived LOX using cadaverine hydrochloride as substrate preincubated for 1 hr followed by substrate addition by ROS-Glo assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
AID1483214Inhibition of human LOXL2 expressed in CHO cells assessed as reduction of H2O2 production from oxidative deamination of DAP preincubated for 2 hrs followed by substrate addition measured every 2 mins for 1 hr by amplex red reagent-based fluorescence assay2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
AID1430576Inhibition of full length recombinant rat LOXL2 expressed in CHO cells assessed as reduction in H2O2 production using DAP as substrate preincubated for 2 hrs followed by substrate addition measured every 2 minutes for 50 minutes in presence of BSA by Ampl2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1483229Irreversible inhibition of human LOXL2 assessed as catalytic activity preincubated for 2 hrs followed by substrate addition measured every 2 mins for 1 hr by amplex red reagent-based fluorescence assay relative to control2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
AID1483215Inhibition of human LOXL2 expressed in CHO cells assessed as reduction of H2O2 production from oxidative deamination of DAP preincubated for 15 mins followed by substrate addition measured every 2 mins for 1 hr by amplex red reagent-based fluorescence ass2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
AID1604043Inhibition of human C-terminal His10-tagged LOXL2 (Met1 to Gln774 residues) expressed in mouse NS0 cells using cadaverine hydrochloride as substrate preincubated for 1 hr followed by substrate addition by ROS-Glo assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
AID1526700Irreversible inhibition of recombinant human C-terminal His-tagged LOLX2 (1-774 residues) expressed in mouse myeloma cells assessed as maximal inhibition at 30XIC50 incubated for 60 mins followed by 100-fold dilution prior to addition of putrescine as sub2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
AID1526666Inhibition of recombinant human C-terminal His-tagged LOLX2 (1-774 residues) expressed in mouse myeloma cells using putrescine as substrate preincubated with enzyme for 30 mins followed by substrate addition and measured every 2.5 mins for 30 mins by Ampl2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
AID1430568Inhibition of full length recombinant human LOXL2 expressed in CHO cells assessed as reduction in H2O2 production using DAP as substrate measured every 2 minutes for 50 minutes by Amplex red dye based fluorescence assay2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1430575Inhibition of full length recombinant mouse LOXL2 expressed in CHO cells assessed as reduction in H2O2 production using DAP as substrate preincubated for 2 hrs followed by substrate addition measured every 2 minutes for 50 minutes in presence of BSA by Am2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1399354Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1399350Inhibition of recombinant LOXL2 (unknown origin) expressed in NS0 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1399352Inhibition of recombinant human LOXL4 expressed in baculovirus infected insect cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1483218Inhibition of human LOX expressed in HEK cells assessed as reduction of H2O2 production from oxidative deamination of DAP preincubated for 2 hrs followed by substrate addition in presence of 0.1% BSA measured every 2 mins for 1 hr by amplex red reagent-ba2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
AID1430573Inhibition of full length recombinant human LOX expressed in HEK cells assessed as reduction in H2O2 production using DAP as substrate preincubated for 2 hrs followed by substrate addition measured every 2 minutes for 50 minutes in presence of BSA by Ampl2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1604048Inhibition of recombinant C-terminal His-tagged human LOXL3 (1 to 753 residues) expressed in CHO cells using cadaverine hydrochloride as substrate preincubated for 1 hr followed by substrate addition by ROS-Glo assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
AID1604042Inhibition of human C-terminal His10-tagged LOXL2 (Met1 to Gln774 residues) expressed in mouse NS0 cells using cadaverine hydrochloride as substrate preincubated for 20 mins followed by substrate addition by ROS-Glo assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
AID1399349Inhibition of recombinant human LOX expressed in HEK293 cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1430566Inhibition of full length recombinant human LOXL2 expressed in CHO cells assessed as reduction in H2O2 production using DAP as substrate preincubated for 15 mins followed by substrate addition measured every 2 minutes for 50 minutes by Amplex red dye base2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1526707Antifibrotic activity in CCl4-induced BALB/c mouse model of liver fibrosis assessed as liver fibrosis area at 2 mg/ml, po administered every 2 day for 6 weeks by picro-sirius red staining based microscopy2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
AID1604044Inhibition of human C-terminal His10-tagged LOXL2 (Met1 to Gln774 residues) expressed in mouse NS0 cells using cadaverine hydrochloride as substrate preincubated for 3 hrs followed by substrate addition by ROS-Glo assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
AID1483216Inhibition of human LOXL2 expressed in CHO cells assessed as reduction of H2O2 production from oxidative deamination of DAP preincubated with enzyme followed by substrate addition measured every 2 mins for 1 hr by amplex red reagent-based fluorescence ass2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
AID1483228Irreversible inhibition of human LOXL2 assessed as reduction of H2O2 production from oxidative deamination of DAP at 1000 times IC50 preincubated for 2 hrs followed by compound washout and subsequent incubation for 2 hrs prior to substrate addition measur2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
AID1430584Ratio of IC50 for full length recombinant human LOX expressed in HEK cells assessed as reduction in H2O2 production in presence of BSA to IC50 for full length recombinant human LOXL2 expressed in CHO cells assessed as reduction in H2O2 production in prese2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1526714Increase in plasma AST level in CCl4-induced BALB/c mouse model of liver fibrosis at 2 mg/ml, po administered every 2 day for 6 weeks2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
AID1604071Irreversible inhibition of human C-terminal His10-tagged LOXL2 (Met1 to Gln774 residues) expressed in mouse NS0 cells at 10 times IC50 using cadaverine hydrochloride as substrate preincubated for 1 hr followed by 100-fold enzyme-compound mixture dilution 2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
AID1526710Increase in plasma ALT level in CCl4-induced BALB/c mouse model of liver fibrosis at 2 mg/ml, po administered every 2 day for 6 weeks2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
AID1483217Inhibition of human LOXL2 expressed in CHO cells assessed as reduction of H2O2 production from oxidative deamination of DAP preincubated for 2 hrs followed by substrate addition in presence of 0.1% BSA measured every 2 mins for 1 hr by amplex red reagent-2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
AID1526730Inhibition of recombinant human C-terminal His-tagged LOLX2 (1-774 residues) expressed in mouse myeloma cells at 10XIC50 preincubated with bound enzyme for 30 mins followed by drug wash-out and later incubated with putrescine substrate and measured after 2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3.
AID1399355Inhibition of recombinant human LOXL3 expressed in CHO cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1430569Inhibition of full length recombinant human LOXL2 expressed in CHO cells assessed as reduction in H2O2 production using DAP as substrate preincubated for 4 hrs followed by substrate addition measured every 2 minutes for 50 minutes by Amplex red dye based 2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1430572Inhibition of full length recombinant human LOXL2 expressed in CHO cells assessed as reduction in H2O2 production using DAP as substrate preincubated for 2 hrs followed by substrate addition measured every 2 minutes for 50 minutes in presence of BSA by Am2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID1399351Inhibition of recombinant human LOXL3 expressed in CHO cells using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1483219Inhibition of recombinant human LOXL2 expressed in human whole blood assessed as reduction of H2O2 production from oxidative deamination of DAP preincubated for 2 hrs followed by substrate addition measured every 2 mins for 1 hr by amplex red reagent-base2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
AID1399353Inhibition of recombinant human LOX expressed in HEK293 cells at 10 uM using diaminopentane as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by fluorimetric method relative to control2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.
AID1430567Inhibition of full length recombinant human LOXL2 expressed in CHO cells assessed as reduction in H2O2 production using DAP as substrate preincubated for 2 hrs followed by substrate addition measured every 2 minutes for 50 minutes by Amplex red dye based 2017ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (904)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990580 (64.16)18.7374
1990's98 (10.84)18.2507
2000's53 (5.86)29.6817
2010's114 (12.61)24.3611
2020's59 (6.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.68 (24.57)
Research Supply Index6.86 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index57.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.42%)5.53%
Reviews38 (3.99%)6.00%
Case Studies2 (0.21%)4.05%
Observational0 (0.00%)0.25%
Other909 (95.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]